How might HPV testing be integrated into cervical screening?
Authors:
- 1 January 2012
- journal article
- editorial
- Published by Elsevier in The Lancet Oncology
- Vol. 13 (1) , 8-10
Abstract
No abstract availableFunding Information
- National Cancer Institute
- National Institutes of Health
This publication has 12 references indexed in Scilit:
- Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trialThe Lancet Oncology, 2012
- Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practiceThe Lancet Oncology, 2011
- Human Papillomavirus Testing in the Prevention of Cervical CancerJNCI: Journal of the National Cancer Institute, 2011
- Long-term Absolute Risk of Cervical Intraepithelial Neoplasia Grade 3 or Worse Following Human Papillomavirus Infection: Role of PersistenceJNCI: Journal of the National Cancer Institute, 2010
- Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trialThe Lancet Oncology, 2010
- Risk estimation for the next generation of prevention programmes for cervical cancerThe Lancet Oncology, 2009
- HPV Screening for Cervical Cancer in Rural IndiaNew England Journal of Medicine, 2009
- Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort studyBMJ, 2008
- Finding a solution to hospital associated infectionsBMJ, 2008
- Human Papillomavirus DNA versus Papanicolaou Screening Tests for Cervical CancerNew England Journal of Medicine, 2007